The University of Northern Ireland, Galway (NUIG) and two Chinese research institutes have signed an agreement to share and exchange research on biomaterials—defined as substances implanted in the body, such as hip implants, stents, heart valves, wound dressings and systems for delivering genes, drugs and vaccines. The Irish Minister for Health, James Reilly, attended the memorandum of understanding signing by NUIG’s president, Jim Browne, M.D., with the Tianjin International Academy of Biotechnology and Medicine and China Nucleon Medical Technology Group.
Irish University Signs Biomaterial IP Accord With China
1 min read Premium comments
Secondary
The China Nucleon Medical Technology Group is regarded as a pioneer in medical imaging for the Chinese pharmaceutical industry and, according to the University, has “extensive facilities for clinical trials and preclinical drug development throughout China.”
The memorandum of understanding will “facilitate the exchange of researchers, the exchange of academic information and the development of collaborative research projects”, according to NUIG in an August 14 press release. Principal investigator Wenxin Wang, M.D., described the agreement as having enormous potential “for the development of new techniques and treatments and for the commercialization and translation of existing technologies to the clinical environment”.
“China is currently emerging as a major player in biomedical research, and establishing these relationships now will pay ever-increasing dividends in the future, ” he said. Browne noted that such partnerships pointed to Ireland’s “global strength in the biomedical sector and the importance of creating linkages which will be of mutual benefit to industry and enterprise both in Ireland and in China”.
The university already has partnerships in China. The existing agreements are with Shanghai Jiao Tong University and the Fourth Medical Military University Hospital in Xi’an. The university’s Regenerative Medicine Institute, which is involved in stem cell research, also has agreements with the Shanghai Institute for Paediatric Research, Bio-X Institutes and the Tangdu Neurosurgery and Neurology Hospital.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.